Stanley Laman Group Ltd. Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,158 shares of the company's stock after acquiring an additional 4,627 shares during the quarter. Neurocrine Biosciences makes up approximately 0.8% of Stanley Laman Group Ltd.'s holdings, making the stock its 26th biggest holding. Stanley Laman Group Ltd.'s holdings in Neurocrine Biosciences were worth $5,755,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Golden State Wealth Management LLC purchased a new position in Neurocrine Biosciences during the 4th quarter valued at about $25,000. Brooklyn Investment Group increased its holdings in Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after buying an additional 115 shares during the period. Blue Trust Inc. raised its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after buying an additional 220 shares in the last quarter. R Squared Ltd purchased a new stake in Neurocrine Biosciences during the fourth quarter worth $61,000. Finally, UMB Bank n.a. boosted its position in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock valued at $62,000 after acquiring an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 2,707 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44. Following the transaction, the director now owns 517,030 shares in the company, valued at approximately $79,064,227.60. This represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the business's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares of the company's stock, valued at $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 236,600 shares of company stock worth $34,348,261 in the last three months. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NBIX shares. Guggenheim decreased their price objective on Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Barclays increased their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday, December 23rd. William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Bank of America lowered their target price on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and an average target price of $166.90.

Neurocrine Biosciences Trading Down 1.6 %

NBIX traded down $1.85 during midday trading on Monday, hitting $115.02. 1,479,784 shares of the company were exchanged, compared to its average volume of 952,604. The firm has a market capitalization of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The company's 50 day simple moving average is $137.83 and its 200 day simple moving average is $130.46. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.